secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001104659-23-039155
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Therapeutics reports FY2022 net loss of $112.7M; cash $28.8M, runway into Q3 2024
--------------------------------------------------------------------------------

- Cash and cash equivalents $28.8M at Dec 31, 2022, down from $53.1M; with $5.5M public offering, runway into Q3 2024.
- Q4 2022 net loss $2.4M ($0.92/share) vs $7.8M ($7.20/share) in Q4 2021; operating loss $2.7M vs $7.8M.
- Full year 2022 net loss $112.7M ($67.99/share) including $76M acquired IPR&D, vs $37.1M in 2021.
- R&D expenses fell to $0.5M in Q4 2022 from $4.5M as legacy trials wrapped; only one active trial vs six.
- ATRN-119 Phase 1/2a enrolling; ATRN-1051 IND filing expected by end of 2023; AACR abstract selected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000110465923039155/0001104659-23-039155-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000110465923039155/tm2310933d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-039155

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer